Track record · closed signal

Innoviva Inc (INVA) — closed signal from May 7, 2026

Partial Published before the outcome was known, scored automatically when the window closed on August 5, 2026 — -13.1% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted

$22.50 – $23.75Entry zone — fair-value band

$23.60Published — price the day we called it

$27.38Target — the price the thesis aimed for

$24.17Peak — highest point inside the window, not a realized return

$20.51Window close — end-of-window price, context only

What happened

Partial

Reached 15% of the predicted growth at its peak, without hitting the target.

At window close

-13.1%

realized, from the publication price to the last close inside the window

Peak gain

+2.4%

peak, from the publication price — not a realized return

S&P 500, same window

+5.5%

SPY over the identical days, dividend-adjusted

Window close

$20.51

last close inside the window, ended August 5, 2026

Peak price

$24.17

peak on June 24, 2026 — not a realized return

Days to target

—

The thesis — published May 7, 2026

Predicted growth

+16%

over the measurement window

Target price

$27.38

the price the thesis aimed for

Entry zone

$22.50 – $23.75

the fair-value band we waited for

Price at publication

$23.60

published May 7, 2026

Confidence

72%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Innoviva is a lower-priced healthcare company that earns steady margins from royalties and investments. Its strong balance sheet helps cushion the risks common to small biotech firms. The stock looks oversold, so a bounce into the earnings period is possible, but thin trading, little company-specific news, and heavy short interest make the outlook uneven.

Primary drivers

Low share price with steady royalty-style profit mix
Solid balance sheet that reduces small-cap biotech risk
Price looks oversold heading into earnings, suggesting a possible bounce
Thin trading, limited company news, and high short interest increase volatility

How it played out

INVA: the 16% growth thesis missed

On May 7, Lyra published a short-term thesis for INVA at $23.60 and expected 16% growth. The thesis pointed to steady royalty-style profits, a solid balance sheet, and an oversold price heading into earnings. It also noted thin trading, limited company news, and high short interest as sources of volatility.

The stock peaked at $24.17 on June 24, a 2.4% gain. It never reached the $27.38 target. By August 5, it had fallen to $20.51, below the publication price. The expected bounce was brief and small compared with the published goal. The thesis did not play out.

What happened during the window

On June 16, Innoviva Specialty Therapeutics announced an exclusive distribution and licensing agreement with Dr. Reddy's for XACDURO in selected international markets. On August 5, Innoviva reported second-quarter results, including $59.8 million in royalty revenue and $36.6 million in U.S. net product sales.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All INVA signals